Details of the Drug Pharmacogenomic Perturbation Atlas

Fluphenazine Drug Info

FLUPHENAZINE; Triflumethazine; Fluorophenazine; Fluorphenazine; Fluorfenazine; Siqualon; Elinol; 69-23-8; Phthorphenazine; Vespazine; Ftorphenazine; Siqualine; Sevinol; Pacinol; Fluphenazinum; Flufenazina; Prolixin; Flufenazin; Dapotum; Flufenazina [DCIT]; Yespazine; SQ 4918; Fluphenazine [INN:BAN]; Moditen (Tabl or elixir); Fluphenazinum [INN-Latin]; 2-(4-(3-(2-(trifluoromethyl)-10H-phenothiazin-10-yl)propyl)piperazin-1-yl)ethanol; 10-(3-(2-Hydroxyethyl)piperazinopropyl)-2-(trifluoromethyl)phenothiazine; UNII-S79426A41Z; HSDB 3334; Dapotum; Prolixine; Fluphenazine hydrochloride; Moditen Hcl; Permitil Concentrate; Prolixin Concentrate; S94; Anatensol (TN); Apo-Fluphenazine; Dapotum (TN); Dapotum D (TN); Dapotum Injektion (TN); Decanoate (TN); Deconoate (TN); Enanthate (TN); Fludecate (TN); Flunanthate (TN); Fluphenazine (INN); Hydrochloride, Fluphenazine; Lyogen (TN); Modecate (TN); Moditen (TN); Moditen Enanthate Injection (TN); Omca (TN); Permitil (TN); Prolixin (TN); Sediten (TN); Selecten (TN); Sevinol (TN); Sinqualone (TN); Trancin (TN)

Therapeutic Class

Antipsychotic Agents

Cross-matching ID

PubChem CID

3372

ChEBI ID

CHEMBL726

CAS Number

CAS 69-23-8

TTD Drug ID

D0P5SA

VARIDT Drug ID

DR00658

INTEDE Drug ID

DR0723

ACDINA Drug ID

D00285

General Information of Drug (ID: DMIT8LX)

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)

Term Name	NES	FDR q-val	Tag %	Leading Edge Genes
Steroid biosynthesis	2.35	0.00e+0	19/20 (95%)	MSMO1;SQLE;DHCR7;...
Lysosome	2.35	0.00e+0	115/128 (89.84%)	NPC1;NEU1;PLA2G15;...
Terpenoid backbone biosynthesis	2.25	0.00e+0	18/22 (81.82%)	HMGCS1;IDI1;HMGCR;...
Biosynthesis of unsaturated fatty acids	2.07	5.50e-3	21/27 (77.78%)	SCD;FADS1;FADS2;...
Amino sugar and nucleotide sugar metabolism	2.02	6.60e-3	38/48 (79.17%)	GNPDA1;UGDH;AMDHD2;...
Synthesis and degradation of ketone bodies	2.02	5.50e-3	9/10 (90%)	HMGCS1;ACAT2
Synaptic vesicle cycle	1.99	6.28e-3	63/78 (80.77%)	STX3;ATP6V1B2;ATP6V1C1;...
PPAR signaling pathway	1.94	9.62e-3	66/74 (89.19%)	HMGCS1;SCD;ACSL3;...
Vibrio cholerae infection	1.92	9.77e-3	44/50 (88%)	ATP6V1B2;TJP2;ATP6V1C1;...
Butanoate metabolism	1.88	1.32e-2	23/28 (82.14%)	HMGCS1;ACAT2;AACS
mTOR signaling pathway	1.85	1.90e-2	114/154 (74.03%)	RRAGD;RRAGC;DDIT4;...
AMPK signaling pathway	1.82	2.38e-2	106/120 (88.33%)	SCD;HMGCR;FASN;...
Cholesterol metabolism	1.79	2.62e-2	44/50 (88%)	NPC1;LDLR;NPC2;...
Sphingolipid metabolism	1.76	3.14e-2	32/49 (65.31%)	NEU1;PLPP3;UGCG;...
Autophagy	1.75	3.66e-2	113/169 (66.86%)	SQSTM1;RRAGD;RRAGC;...
Collecting duct acid secretion	1.72	4.47e-2	22/27 (81.48%)	ATP6V1B2;ATP6V1C1;ATP6V1G1;...
Phagosome	1.71	4.53e-2	118/152 (77.63%)	TUBB2A;CD36;THBS2;...
One carbon pool by folate	-1.50	4.65e-2	15/20 (75%)	GART;ATIC;MTHFD1;...
Caffeine metabolism	-1.51	4.49e-2	5/6 (83.33%)	XDH;CYP2A6;NAT2;...
Amyotrophic lateral sclerosis	-1.52	4.31e-2	267/364 (73.35%)	PSMB4;MAPK11;ATP5MC2;...
Oxidative phosphorylation	-1.52	4.44e-2	93/133 (69.92%)	NDUFS3;NDUFS1;ATP5MC2;...
Ribosome biogenesis in eukaryotes	-1.52	4.58e-2	52/108 (48.15%)	GNL3L;PWP2;RRP7A;...
Glycosylphosphatidylinositol (GPI)-anchor biosynthesis	-1.54	4.41e-2	20/26 (76.92%)	PIGN;PIGV;GPAA1;...
p53 signaling pathway	-1.56	3.70e-2	63/73 (86.3%)	CDKN2A;CASP8;CASP9;...
Sulfur relay system	-1.58	3.24e-2	5/8 (62.5%)	MOCS2;NFS1
Autoimmune thyroid disease	-1.59	3.35e-2	46/53 (86.79%)	CTLA4;HLA-DOB;HLA-DRB1;...
Thermogenesis	-1.59	3.48e-2	173/232 (74.57%)	MAPK11;ATP5MC2;ATP5MG;...
Mannose type O-glycan biosynthesis	-1.60	3.45e-2	14/23 (60.87%)	CHST10;B3GAT1;FKTN;...
Folate biosynthesis	-1.61	3.47e-2	23/26 (88.46%)	SPR;MOCS1;PTS;...
Graft-versus-host disease	-1.64	2.51e-2	32/42 (76.19%)	KIR3DL1;KIR2DL3;KLRD1;...
Huntington disease	-1.69	1.77e-2	233/306 (76.14%)	POLR2D;NRF1;COX4I1;...
Ribosome	-1.70	1.54e-2	113/158 (71.52%)	RPL39;RPL24;RPL15;...
RNA transport	-1.75	8.46e-3	128/186 (68.82%)	CASC3;TACC3;GEMIN6;...
Prion disease	-1.79	3.97e-3	209/273 (76.56%)	PSMB4;MAPK11;ATP5MC2;...
Parkinson disease	-1.80	4.27e-3	176/249 (70.68%)	PSMB4;ATP5MC2;EIF2S1;...
Spliceosome	-1.83	3.31e-3	101/150 (67.33%)	DHX38;HNRNPK;DDX42;...
Nucleotide excision repair	-1.87	2.89e-3	40/47 (85.11%)	POLE;POLD1;POLD3;...
RNA degradation	-1.89	2.38e-3	53/79 (67.09%)	PAN2;LSM3;MPHOSPH6;...
Fanconi anemia pathway	-1.90	2.64e-3	36/54 (66.67%)	RAD51;FANCA;RPA3;...
Systemic lupus erythematosus	-1.90	2.98e-3	45/135 (33.33%)	C9;CD80;SNRPD1;...
Aminoacyl-tRNA biosynthesis	-1.95	3.40e-3	15/66 (22.73%)	DARS2;HARS2;SARS2;...
Base excision repair	-1.96	2.64e-3	29/33 (87.88%)	APEX1;SMUG1;HMGB1;...
Cell cycle	-2.01	1.59e-3	110/124 (88.71%)	STAG2;TP53;ANAPC1;...
Homologous recombination	-2.01	1.98e-3	35/41 (85.37%)	BLM;SEM1;BRIP1;...
Proteasome	-2.16	0.00e+0	44/46 (95.65%)	PSMC2;PSMA7;PSMD1;...
Mismatch repair	-2.36	0.00e+0	22/23 (95.65%)	MSH3;POLD1;POLD3;...
DNA replication	-2.61	0.00e+0	34/36 (94.44%)	POLE3;POLA2;POLE;...

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone

Osteosarcoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
U-2 OS	CVCL_0042	Homo sapiens	20uM	6H

Breast

Breast adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point
MCF7	CVCL_0031	Homo sapiens	0.01uM - 10uM	6H, 24H

MDA-MB-231	CVCL_0062	Homo sapiens	0.01uM - 10uM	24H

Breast epithelium

Normal

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
MCF-10A	CVCL_0598	Homo sapiens	0.01uM - 10uM	24H

Cervix

Cervical adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HeLa	CVCL_0030	Homo sapiens	0.01uM - 10uM	24H

Colon

Colorectal adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HT-29	CVCL_0320	Homo sapiens	0.01uM - 10uM	6H, 24H

Hematopoietic system

Normal

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
ASC	CVCL_U602	Homo sapiens	10uM	24H

Kidney

Normal (Immortalized)

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HA1E	CVCL_0284	Homo sapiens	0.01uM - 10uM	6H, 24H

Normal (Transformed)

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HEK293	CVCL_0045	Homo sapiens	0.01uM - 10uM	24H

Liver

Hepatoblastoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
Hep G2	CVCL_0027	Homo sapiens	10uM	6H

Hepatocellular carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HuH-7	CVCL_0336	Homo sapiens	8uM	72H

Lung

Lung adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A549	CVCL_0023	Homo sapiens	0.01uM - 10uM	6H, 24H

Non-small cell lung carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HCC515	CVCL_5134	Homo sapiens	10uM	6H, 24H

Pancreas

Pancreatic carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
YAPC	CVCL_1791	Homo sapiens	0.01uM - 10uM	24H

Peripheral blood

Acute monocytic leukemia

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
THP-1	CVCL_0006	Homo sapiens	0.01uM - 2.22uM	24H

T-cell acute lymphoblastic leukemia

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
Jurkat	CVCL_0367	Homo sapiens	0.01uM - 10uM	24H

Prostate

Prostate carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point
PC-3	CVCL_0035	Homo sapiens	0.01uM - 10uM	6H, 24H

VCaP	CVCL_2235	Homo sapiens	1.11uM - 20uM	6H, 24H, 48H

Skin

Melanoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A-375	CVCL_0132	Homo sapiens	0.01uM - 10uM	6H, 24H